Immunotherapy Coverage from Every Angle

Recent News

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma
AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma
SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML
SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma
Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer
Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?
Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC
Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma
Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer
Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer
Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?
Combination Checkpoint Antibody Treatment in Cutaneous Squamous Cell Carcinoma
FDA Approves Nivolumab as First Adjuvant Treatment for High-Risk Urothelial Carcinoma
Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma
Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL
Urothelial Carcinoma: Prognostic Factors Associated With Immune Checkpoint Inhibitors
Lenvatinib Plus Pembrolizumab Approved by FDA for Advanced Renal Cell Carcinoma
Atezolizumab Receives Priority Review From the FDA in Early NSCLC
ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma
Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML
Atezolizumab in Resistant Advanced Urothelial Cancer: Prognostic Significance of Pretreatment Factors
JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer
PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC
Use of Avelumab for Oligoprogression in Advanced Merkel Cell Carcinoma: Case Report
Adding Atezolizumab to Chemotherapy for Muscle-Invasive Bladder Cancer
Checking Checkpoint Inhibitor Effectiveness in Immunocompromised Patients With Advanced Skin Cancer
MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study
Patterns of PD-L1 Expression in NSCLC Harboring Driver Oncogene Mutations Including NTRK Fusions
Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC
Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma
Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer
Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?
Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma
Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?
Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma
Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy
Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.